Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
3,454
Views
32
CrossRef citations to date
0
Altmetric
Editorial

Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death

Lígia C. Gomes-da-Silvaa CQC, Coimbra Chemistry Center, University of Coimbra, Coimbra, PortugalORCID Iconhttps://orcid.org/0000-0003-0624-8819View further author information
ORCID Icon,
Oliver Keppb Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;c Equipe 11 labellisée Ligue Contre le Cancer, Université de Paris, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6081-9558View further author information
ORCID Icon &
Guido Kroemerb Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;c Equipe 11 labellisée Ligue Contre le Cancer, Université de Paris, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, Paris, France;d Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;e Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou, Jiangsu, China;f Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405View further author information
ORCID Icon
Article: 1841393 | Received 12 Oct 2020, Accepted 20 Oct 2020, Published online: 27 Oct 2020

Figures & data

Figure 1. Mechanism of cetuximab saratolacan. Cetuximab-bound IR700 selectively binds to the surface of EGFR+ tumor cells. Its photo-activation at 690 nm selectively kills EGFR-expressing cells, thus allowing for targeted photodynamic therapy (PDT) and the induction of immunogenic cell death (ICD). This elicits a systemic immune response that contributes to the eradication of malignant cells. CTLs, cytotoxic T lymphocytes; DCs, dendritic cells

Figure 1. Mechanism of cetuximab saratolacan. Cetuximab-bound IR700 selectively binds to the surface of EGFR+ tumor cells. Its photo-activation at 690 nm selectively kills EGFR-expressing cells, thus allowing for targeted photodynamic therapy (PDT) and the induction of immunogenic cell death (ICD). This elicits a systemic immune response that contributes to the eradication of malignant cells. CTLs, cytotoxic T lymphocytes; DCs, dendritic cells

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.